The Medical University of Vienna has filed a new patent application for extended protection of T20K, included in Cyxone’s license agreement

Cyxone (publ), a Swedish biotech in autoimmune diseases, announces today that the Medical University of Vienna has filed a new patent application for extended protection of T20K in multiple sclerosis (MS). The patent is included in Cyxone’s license agreement with the Medical University and is entitled “Cyclotides in combination with kappa opioid receptor ligands for multiple sclerosis therapy”.

With this extended patent, Cyxone will have more therapeutic options for their cyclotides, a wider patent protection and a new priority date.

 

Contact

Ola Skanung, interim CEO & CFO

Tel: +46 (0) 705 121 040

Email: ola.skanung@cyxone.com 

Adelgatan 21

211 22 Malmö

www.cyxone.com

 

About Cyxone

Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in clinical phase I program and Rabeximod for RA in clinical phase II program. Cyxone’s Certified Adviser on the Nasdaq First North Growth Market is Mangold Fondkommission AB, +46 (0)8-503 015 50, ca@mangold.se. www.cyxone.com

Tags:

Subscribe

Documents & Links